Cantor Fitzgerald Has Weak Forecast for CRSP FY2025 Earnings

CRISPR Therapeutics AG (NASDAQ:CRSP - Free Report) - Equities research analysts at Cantor Fitzgerald lowered their FY2025 earnings per share (EPS) estimates for CRISPR Therapeutics in a report released on Wednesday, February 19th. Cantor Fitzgerald analyst E. Schmidt now expects that the company will post earnings per share of ($6.91) for the year, down from their previous forecast of ($5.08). Cantor Fitzgerald has a "Neutral" rating on the stock. The consensus estimate for CRISPR Therapeutics' current full-year earnings is ($5.16) per share.

CRISPR Therapeutics (NASDAQ:CRSP - Get Free Report) last posted its quarterly earnings results on Tuesday, February 11th. The company reported ($0.44) earnings per share (EPS) for the quarter, beating the consensus estimate of ($1.15) by $0.71. CRISPR Therapeutics had a negative return on equity of 18.46% and a negative net margin of 981.54%.

CRSP has been the topic of several other research reports. Barclays raised their price target on CRISPR Therapeutics from $55.00 to $56.00 and gave the company an "equal weight" rating in a report on Wednesday, February 12th. StockNews.com upgraded CRISPR Therapeutics to a "sell" rating in a report on Thursday, February 13th. TD Cowen upgraded CRISPR Therapeutics from a "sell" rating to a "hold" rating and set a $35.00 target price on the stock in a report on Wednesday, February 12th. Needham & Company LLC restated a "buy" rating and set a $84.00 target price on shares of CRISPR Therapeutics in a report on Wednesday, February 12th. Finally, Truist Financial raised their target price on CRISPR Therapeutics from $100.00 to $120.00 and gave the stock a "buy" rating in a report on Wednesday, February 12th. Two equities research analysts have rated the stock with a sell rating, nine have issued a hold rating and twelve have assigned a buy rating to the company's stock. According to data from MarketBeat.com, the company has a consensus rating of "Hold" and an average price target of $74.40.

CRISPR Therapeutics Trading Down 5.0 %

CRISPR Therapeutics stock traded down $2.52 during mid-day trading on Friday, hitting $47.91. The stock had a trading volume of 2,671,174 shares, compared to its average volume of 2,550,435. The stock has a 50-day simple moving average of $42.25 and a two-hundred day simple moving average of $46.06. The stock has a market capitalization of $4.11 billion, a PE ratio of -10.96 and a beta of 1.67. CRISPR Therapeutics has a 12 month low of $36.52 and a 12 month high of $91.10.

Hedge Funds Weigh In On CRISPR Therapeutics

Several hedge funds have recently made changes to their positions in CRSP. ARK Investment Management LLC grew its stake in shares of CRISPR Therapeutics by 19.7% during the 4th quarter. ARK Investment Management LLC now owns 8,973,064 shares of the company's stock worth $353,180,000 after acquiring an additional 1,474,439 shares in the last quarter. T. Rowe Price Investment Management Inc. grew its stake in shares of CRISPR Therapeutics by 39.2% in the fourth quarter. T. Rowe Price Investment Management Inc. now owns 3,811,708 shares of the company's stock valued at $150,029,000 after buying an additional 1,074,238 shares in the last quarter. Capital International Investors grew its stake in shares of CRISPR Therapeutics by 10.3% in the fourth quarter. Capital International Investors now owns 8,743,523 shares of the company's stock valued at $344,145,000 after buying an additional 816,789 shares in the last quarter. Baker BROS. Advisors LP grew its stake in shares of CRISPR Therapeutics by 743.1% in the third quarter. Baker BROS. Advisors LP now owns 843,075 shares of the company's stock valued at $39,608,000 after buying an additional 743,075 shares in the last quarter. Finally, State Street Corp grew its stake in shares of CRISPR Therapeutics by 25.0% in the third quarter. State Street Corp now owns 2,992,988 shares of the company's stock valued at $140,611,000 after buying an additional 599,304 shares in the last quarter. 69.20% of the stock is owned by institutional investors.

Insider Transactions at CRISPR Therapeutics

In other news, CEO Samarth Kulkarni sold 15,000 shares of the firm's stock in a transaction that occurred on Monday, December 2nd. The shares were sold at an average price of $55.10, for a total transaction of $826,500.00. Following the completion of the transaction, the chief executive officer now directly owns 181,540 shares of the company's stock, valued at $10,002,854. This trade represents a 7.63 % decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Company insiders own 4.10% of the company's stock.

About CRISPR Therapeutics

CRISPR Therapeutics is a gene-editing company focused on developing transformative gene-based medicines for serious diseases using its proprietary CRISPR/Cas9 platform. CRISPR/Cas9 is a revolutionary gene-editing technology that allows for precise, directed changes to genomic DNA. CRISPR Therapeutics has established a portfolio of therapeutic programs across a broad range of disease areas including hemoglobinopathies, oncology, regenerative medicine and rare diseases.